Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
38.84
-0.65 (-1.65%)
Sep 3, 2026, 3:36 PM EDT - Market open

Immunovant Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
8,0235,0562,9034,6942,005641
Market Cap Growth
213.29%74.16%-38.16%134.16%212.60%-59.19%
Enterprise Value
7,2254,0612,5284,0041,574117
Last Close Price
39.4924.8417.0932.3115.515.51

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
11.085.934.107.605.531.37
P/TBV Ratio
11.005.934.107.605.531.37

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
-0000.000.01
Net Debt / Equity Ratio
-1.08-1.06-1.01-1.03-1.03-1.05
Net Debt / EBITDA Ratio
1.411.691.632.351.803.15
Net Debt / FCF Ratio
1.932.221.902.961.994.62
Quick Ratio
6.828.6810.4213.188.7211.38
Current Ratio
7.279.0911.1613.709.3411.52
Return on Equity (ROE)
-80.10%-64.82%-62.46%-52.91%-50.69%-36.39%
Return on Assets (ROA)
-46.73%-38.43%-37.97%-31.50%-28.26%-21.02%
Return on Capital Employed (ROCE)
-77.00%-62.50%-61.90%-43.70%-57.40%-33.10%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Earnings Yield
-6.66%-10.00%-14.26%-5.52%-10.52%-24.44%
FCF Yield
-5.12%-8.06%-12.97%-4.57%-9.40%-16.59%
Buyback Yield / Dilution
-21.12%-20.35%-9.76%-12.21%-12.21%-24.98%
SEC Filings: 10-K · 10-Q